Fig. 5

Reductions in tumor-binding valency critically impair T-BsAb efficacy in vitro and in vivo (A) Geometric mean fluorescent intensity of T-BsAbs against SW1990 cells measured by FACS. (B) Antibody-dependent T cell-mediated cytotoxicity (ADTC) assays targeting SW1990 cells. (C) Tumor growth of subcutaneous SW1990 xenograft (left) and survival (right). 2 × 10⁷ T cells were administered per infusion. 10µg T-BsAbs were administered i.v. twice a week. (D) IHC of 1aS1 tumors. (E) Tumor growth of subcutaneous 1aS1 patient-derived PDAC xenograft (left) and survival (right). 2 × 10⁷ T cells were administered per infusion. 2µg T-BsAbs were administered i.v. twice a week (n = 4 mice per group)